A pharmaceutical campaign to thwart the coronavirus suffered twin setbacks this week, with Johnson & Johnson pausing its late-stage vaccine trial because of an unexplained illness and a separate drugmaker taking a time-out as it vets a neutralizing antibody treatment, the Washington Times website reports today (October 13, 2020).
"We're letting safety protocol follow proper procedure here," J & J Chief Financial Officer Joseph Wolk said today. "Pauses are something that's not uncommon."
He noted that 60,000 people are involved in the study, so an adverse event isn't shocking.
Also today, drugmaker Eli Lilly said its data safety monitoring board recommended a pause in the clinical trial of its monoclonal antibody treatment. It did not specify what the safety concern was.
No comments:
Post a Comment